Full history for every metric is available with a Kvantra account
Turnstone Biologics Corp. (TSBX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 101 | 73 | 19 | 0 | 2 |
| Operating profit | $m | -72 | -44 | |||||
| Net profit | $m | - | - | 33 | -31 | -55 | -71 | -47 |
| EPS reported | $ | -3.07 | -2.05 | |||||
| Operating cashflow per share | $ | -2.93 | -0.49 | |||||
| Capex per share | $ | 0.01 | 0.00 | |||||
| FCF per share | $ | -2.94 | -0.49 | |||||
| Free cash flow | $m | -68 | -45 | |||||
| Net debt | $m | -29 | -17 | |||||
| Book value equity | $m | 31 | 15 | |||||
| Book value per share | $ | 1.37 | 0.64 | |||||
| Number of shares | m | 23.04 | 23.14 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.36 | 0.56 | |||||
| P/S LTM | x | 0.00 | 4.07 | |||||
| P/FCF LTM | x | -0.17 | -0.18 | |||||
| EV/EBITDA LTM | x | 0.24 | 0.18 | |||||
| EV/Sales LTM | x | 0.00 | -4.20 | |||||
| Earnings Yield LTM | % | -618.82% | -210.54% | |||||
| FCF Yield | % | -591.13% | -551.87% | |||||
| Quality | ||||||||
| ROE | % | -225.12% | -99.55% | |||||
| ROIC | % | -219.51% | -93.46% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -56.91 | -110.31 | |||||
| Net Debt/EBITDA | x | 0.40 | 0.95 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -252.69% | -203.14% | |||||
| Net debt/Equity | x | -0.92 | -1.13 | |||||
| Gross debt/equity | x | 0.04 | 0.03 | |||||
Company overview
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free